

18 November 2011

The Manager Companies
ASX Limited
20 Bridge Street
Sydney NSW 2000

(2 pages by email)

BIOTRON SELECTED TO PRESENT AT INTERNATIONAL HEPATITIS CONFERENCE

Phase 2a data to be released

Sydney, Australia: 18 November 2011: Australian drug development company Biotron Limited (ASX: BIT) will release data from its recent phase 2a trial of the company's lead anti-Hepatitis C virus (HCV) drug BIT225 at an international conference beginning on 4 December 2011.

Biotron has been selected to present at the well-regarded HepDART conference, a bi-annual event, enabling clinicians, researchers and industry authorities to communicate new drug developments for viral hepatitis.

In the presentation, Biotron will release results from Biotron's recent phase 2a trial on 24 patients at the Siriraj Hospital, Bangkok, Thailand. Patients involved in the study were randomly assigned to receive either 400 mg or 200 mg BIT 225 or placebo along with standard anti-retroviral drug candidates.

The Company reported in October that a preliminary analysis of trial data had confirmed that BIT225, an orally administered, first-in-class new small molecule drug, had good antiviral activity against HCV.

These early results indicated patients receiving BIT225 in combination with Interferon and Ribavarin (the current standard of care treatment for treating HCV) had greater reductions in HCV levels than patients receiving standard of care treatment alone.

Biotron CEO Dr Michelle Miller said that while the preliminary data had been extremely encouraging, she expected these early results would be further validated by the comprehensive results.

“All indications from this phase 2a trial so far have been extremely positive. The international HCV community has been waiting on release of this full data” she said.

The HepDART conference will run from 4 to 8 December 2011 in the USA.

Enquiries

Dr Michelle Miller
Managing Director
Biotron Limited
+61-2 9805 0488

Rudi Michelson
Monsoon Communications
+61-3 9620 3333

Yours faithfully



Peter J. Nightingale
Company Secretary

pjn6351

About Biotron

Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need, with a major focus on HIV and HCV. The Company has BIT225 in clinical development for both HCV and HIV, and also has several earlier stage preclinical and research programs for several other viral infections including influenza, Dengue and Hepatitis B.

About BIT225 and HCV

BIT225 is an investigational, orally-administered, novel antiviral compound in development by Biotron for treatment of HCV. BIT225 represents a first-in-class drug, targeting the p7 protein of HCV. It is estimated that in the USA alone, some 4 million people have been infected with Hepatitis C with 2.7 million suffering from chronic infection. Worldwide, 170 million people are infected.

HCV causes inflammation of the liver, which may lead to fibrosis and cirrhosis, liver cancer and, ultimately, liver failure. Existing drugs for HCV have limited effectiveness and toxicity issues, leaving a significant need for new therapies. The worldwide market is currently almost US\$3.3 billion, but is estimated that this market will expand to over US\$10.0 billion as safe, effective therapies enter the market.